Support for you and your patients with IBS-D

The resources below include information about dosing, insurance requirements,* and the science behind XIFAXAN. You’ll also find materials to share with your patients to help them understand treatment with XIFAXAN and keep track of their IBS-D symptoms.

XIFAXAN IBS-D Flashcard thumbnail

An overview of key clinical information about IBS-D and treatment with XIFAXAN.

Xifaxan dosing flashcard thumbnail
XIFAXAN Dosing Flashcard

A summary of dosing information for prescribing XIFAXAN.

PA considerations handout thumbnail
Prior Authorization (PA) Considerations Handout

Keep easy-to-follow directions on hand to help make PA submissions simple for XIFAXAN. Includes both IBS-D and OHE indications.

Letter of Medical Necessity thumbnail
Sample Letter of Medical Necessity

A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

Tier exemption request thumbnail
Tier Exemption Request

A Tier Exemption Request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.

IBS-D, irritable bowel syndrome with diarrhea; OHE, overt hepatic encephalopathy.

*Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

Xifaxan patient brochure thumbnail
XIFAXAN Patient Brochure

Keep patients informed about what it means to have and treat IBS-D with XIFAXAN.

IBS-D and Xifaxan information sheet
IBS-D Symptom Tracker

Help patients identify possible symptoms of IBS-D.

Xifaxan Copay card thumbnail

Instant Savings Card

Available for eligible, commercially insured patients.

HE, hepatic encephalopathy; IBS-D, irritable bowel syndrome with diarrhea.

*Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.


XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.